33results about How to "Prolong blood half-life" patented technology

The present invention relates to a pharmaceutical composition for the prevention and treatment of non-alcoholic fatty liver disease (NAFLD), including a conjugate prepared by covalently linking an insulinotropic peptide, a non-peptidyl polymer and an immunoglobulin Fc region. The composition of the present invention maintains the in-vivo activity of the peptide at a relatively high level, and remarkably increases the blood half-life, thereby preventing triglyceride accumulation which is a typical feature of non-alcoholic fatty liver disease. Ultimately, it can be desirably employed for the prevention and treatment of non-alcoholic fatty liver disease.

The purpose of the invention is to provide a glucan containing at least one residue selected from an N-acetylglucosamine residue and a galactose residue, and a modified product thereof. A branched glucan according to the invention is a branched glucan in which at least one residue selected from an N-acetylglucosamine residue and a galactose residue is linked via an a-1,4-linkage to each of two or more non-reducing ends among a plurality of non-reducing ends of a branched a-1,4-glucan, and at positions other than the non-reducing ends of the branched a-1,4-glucan, either of an N-acetylglucosamine residue or a galactose residue is not present.

The invention provides an active targeting type amphipathic polypeptide nano-drug carrier and preparation and application thereof, and belongs to the technical field of biological medicines. According to an amphipathic polypeptide, an alkyl chain serves as the hydrophobic end, a polypeptide chain with active targeting functional and side chain modification fluorescent functional molecules serves as the hydrophilic end, and an anti-tumor drug is wrapped in a hydrophobic cavity of a micelle formed by self-assembling the amphipathic polypeptide. The nano-carrier can actively target tumor cells and enter the tumor cells through receptor-mediated endocytosis, the amphipathic polypeptide and phospholipid molecules have strong interaction, and the phagocytosis of a nano-drug by tumor cells is promoted. In the process, tracing can be conducted through fluorescent imaging of fluorescent functional molecules modified on the polypeptide chain, and the tumor imaging aim is realized. Finally, the anti-tumor drug is slowly released to kill tumor cells and restrain the growth of tumors. The amphipathic polypeptide nano-carrier is free of toxin, high in biocompatibility and remarkable in anti-tumor efficiency, and the tumor diagnosis and treatment can be integrated.

The present invention provides a low-molecular-weight heparin sustained-release preparation, a preparation method and application thereof, wherein the low-molecular-weight heparin sustained-release preparation comprises nanoparticles formed by polypeptides and low molecular weight heparin, and the polypeptides are cross-linked through chemical bonds. The present invention adopts any one or a combination of at least two of self-assembly technology, freeze-drying technology, homogenization technology, emulsification technology, embedding technology or spray-drying technology to prepare low molecular weight heparin sustained-release preparation. The low-molecular-weight heparin sustained-release preparation of the invention has a release rate of only about 20% within 500 hours under in vitro conditions, has a sustained-release effect, can effectively prolong its blood half-life, avoid the "peak-to-valley fluctuation" of the drug, and reduce the dosage of the low-molecular-weight heparin solution. The risk of hemorrhage when the dose is used, the toxic and side effects of the drug are reduced, the compliance of patients is improved, and the treatment efficiency of the disease is improved, and can be used for the prevention and treatment of thrombosis diseases. The preparation method of the invention is simple and has broad application prospects.

The invention provides a medicinal composition and a preparation method thereof. The medicinal composition comprises a carrier and an active component loaded on the carrier, wherein the carrier is nano particles of cyclodextrin-aliphatic polyester-phosphatidyl ethanolamine graft polymer with the structural formula shown in a formula (1) in the specifications; and in the formula (1), m is an integer from 6 to 8, and G is an oxygen atom or has a formula shown in the specifications.

Provided is a method of preparing a physiologically active polypeptide conjugate, in which a physiologically active polypeptide and a non-peptidyl polymer are linked to each other via a covalent bond. The method is to improve an overall yield of the physiologically active polypeptide conjugate by improving a reaction of the non-peptidyl polymer and the physiologically active polypeptide, and particularly, the method is to prepare a physiologically active polypeptide conjugate in a high yield by performing a two-step reaction through selective precipitation. The preparation method of the present invention is used to produce a non-peptidyl polymer-physiologically active polypeptide conjugate and a physiologically active polypeptide-physiologically active carrier conjugate in a high yield, and therefore, the method may be used in the development of long-acting formulations of various peptide drugs which maintain in vivo activity at a relatively high level and have remarkably increased blood half-life.

The invention discloses a radioactive iodine marked protein binding ligand and application thereof. A structural formula of the radioactive iodine marked protein binding ligand is shown in a followingimage, wherein the I is radioactive iodine nuclide, the R is OH or derived from PEG, folic acid, RGD, octreotide, epidermal growth factor, protein, nucleic acid or polysaccharide. The radioactive iodine marked protein binding ligand disclosed by the invention has the advantages of simple marking method, low cost and good stability. Animal live test results show that the albumin binding ligand hashigher uptake and longer-time retention in blood and further has a higher target / non-target specific value. When the radioactive iodine marked protein binding ligand is modified to a target group orother functional groups, pharmacokinetic characters of compound can be obviously improved, a blood half-life period of the compound is prolonged, and the compound is suitable for being utilized as a blood pool, lymph and tumor diagnosing and treating reagent.